This Article Full Text Full Text (PDF) All Versions of this Article: 36/3/e17    most recent 01.STR.0000155738.02753.4dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wolff, V. Articles by Lanza, F. Search for Related Content PubMed PubMed Citation Articles by Wolff, V. Articles by Lanza, F. Pubmed/NCBI databases Medline Plus Health Information Stroke Transient Ischemic Attack Related Collections Arterial thrombosis Coagulation Thrombin Acute Stroke Syndromes Anticoagulants Antiplatelets Platelets

(Stroke. 2005;36:e17.)
© 2005 American Heart Association, Inc.

Short Communication

Soluble Platelet Glycoprotein V Is a Marker of Thrombosis in Patients With Ischemic Stroke

Valérie Wolff, MD; Boris Aleil, MD, PhD; Maurice Giroud, MD; Jean-Louis Lorenzini, MD; Nicolas Meyer, MD; Marie-Louise Wiesel, MD; Jean-Pierre Cazenave, MD, PhD François Lanza, PharmD, PhD

From the Etablissement Français du Sang—Alsace (V.W., B.A., M.-L.W., J.-P.C., F.L.), Institut National de la Santé et de la Recherche Médicale U.311, Strasbourg, France; Service de Neurologie (V.W.), Hôpital Civil, Strasbourg, France; Service de Neurologie (M.G.), Centre Hospitalier Universitaire, Dijon, France; Laboratoire d’Hématologie (J.-L.L.), Hôpital du Bocage, Dijon, France; and Département de Santé Publique (N.M.), Hôpital Civil, Strasbourg, France.

Correspondence to François Lanza, EFS—Alsace, 10 rue Spielmann, B.P. N° 36, F-67065 Strasbourg Cedex, France. E-mail francois.lanza{at}efs-alsace.fr

Background and Purpose— The diagnosis and management of patients with acute ischemic stroke still lack an informative biochemical test. Soluble glycoprotein V (sGPV) is a new plasmatic marker of thrombosis released from the platelet surface by thrombin. The objective of this prospective study was to compare the levels of sGPV in stroke and control patients.

Methods— Consecutive patients with acute ischemic stroke (n=159) and controls (n=70) were recruited for sGPV measurement.

Results— Plasmatic levels of sGPV were significantly increased in ischemic stroke compared with control patients (median [interquartile range] 39.4 [31.8 to 52.9] versus 28.1 [24.0 to 37.9] ng/mL; P<0.0001). In multivariate analysis, ischemic stroke was the major determinant of the sGPV increase (odds ratio [95% CI], 5.87 [2.62 to 13.12]; P<0.0001).

Conclusions— sGPV is a new marker of arterial thrombosis and represents a tool to study the mechanisms involved in ischemic stroke. The increase in plasmatic sGPV observed in stroke patients supports a role of platelets and thrombin in the events leading to ischemic stroke.

Key Words: platelets • stroke • thrombosis